The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex
- Xiao Jie Yaoa,
- Gisselle Vélez Ruizb,
- Matthew R. Whortonb,
- Søren G. F. Rasmussena,
- Brian T. DeVreeb,
- Xavier Deupic,
- Roger K. Sunaharab,1 and
- Brian Kobilkaa,1
- aDepartment of Molecular and Cellular Physiology, Stanford University Medical School Department of Chemistry, Stanford University, Stanford, CA 94305;
- bDepartment of Pharmacology, University of Michigan Medical School, 1301 Medical Sciences Research Building III, Ann Arbor, MI 48109; and
- cLaboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Catalunya, Spain
-
Edited by Robert J. Lefkowitz, Duke University Medical Center, Durham, NC, and approved April 14, 2009 (received for review November 11, 2008)
Abstract
G protein-coupled receptors (GPCRs) mediate the majority of physiologic responses to hormones and neurotransmitters. However, many GPCRs exhibit varying degrees of agonist-independent G protein activation. This phenomenon is referred to as basal or constitutive activity. For many of these GPCRs, drugs classified as inverse agonists can suppress basal activity. There is a growing body of evidence that basal activity is physiologically relevant, and the ability of a drug to inhibit basal activity may influence its therapeutic properties. However, the molecular mechanism for basal activation and inhibition of basal activity by inverse agonists is poorly understood and difficult to study, because the basally active state is short-lived and represents a minor fraction of receptor conformations. Here, we investigate basal activation of the G protein Gs by the β2 adrenergic receptor (β2AR) by using purified receptor reconstituted into recombinant HDL particles with a stoichiometric excess of Gs. The β2AR is site-specifically labeled with a small, environmentally sensitive fluorophore enabling direct monitoring of agonist- and Gs-induced conformational changes. In the absence of an agonist, the β2AR and Gs can be trapped in a complex by enzymatic depletion of guanine nucleotides. Formation of the complex is enhanced by the agonist isoproterenol, and it rapidly dissociates on exposure to concentrations of GTP and GDP found in the cytoplasm. The inverse agonist ICI prevents formation of the β2AR-Gs complex, but has little effect on preformed complexes. These results provide insights into G protein-induced conformational changes in the β2AR and the structural basis for ligand efficacy.
Footnotes
- 1To whom correspondence may be addressed. Email: kobilka{at}stanford.edu or sunahara{at}umich.edu
-
Author contributions: X.D., R.K.S., and B.K. designed research; X.J.Y., G.V.R., M.R.W., S.G.F.R., and B.T.D. performed research; X.J.Y., X.D., R.K.S., and B.K. analyzed data; and R.K.S. and B.K. wrote the paper.
-
The authors declare no conflict of interest.
-
This article is a PNAS Direct Submission.
-
This article contains supporting information online at www.pnas.org/cgi/content/full/0811437106/DCSupplemental.
-
Freely available online through the PNAS open access option.










